Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial
Morag Griffin,
Shreyans Gandhi,
Richard J. Kelly,
Talha Munir,
Roochi Trikha,
Eden Hicks,
Deepak Jain,
Masayo Ogawa,
Ji Yu,
Petra Muus,
Austin G. Kulasekararaj
Affiliations
Morag Griffin
St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds
Shreyans Gandhi
King’s College Hospital, National Institute for Health and Care Research (NIHR) Wellcome Trust King’s Clinical Research Facility, London
Richard J. Kelly
St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds
Talha Munir
St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds
Roochi Trikha
King’s College Hospital, National Institute for Health and Care Research (NIHR) Wellcome Trust King’s Clinical Research Facility, London
Eden Hicks
Alexion, AstraZeneca Rare Disease, Boston, MA
Deepak Jain
Alexion, AstraZeneca Rare Disease, Boston, MA
Masayo Ogawa
Alexion, AstraZeneca Rare Disease, Boston, MA
Ji Yu
Alexion, AstraZeneca Rare Disease, Boston, MA
Petra Muus
St James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds
Austin G. Kulasekararaj
King’s College Hospital, National Institute for Health and Care Research (NIHR) Wellcome Trust King’s Clinical Research Facility, London, UK; King’s College London, London
